RNS Number : 4819Y
BiVictriX Therapeutics PLC
04 May 2023
 

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

 

 

Result of Annual General Meeting

 

Alderley Park, 4th May 2023 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies with improved tolerability and anti-cancer activity, announces that at the Company's Annual General Meeting held today at 11:30 am at the Company's registered office, Mereside Alderley Park, Alderley Edge, Manchester SK10 4TG, all resolutions were duly passed. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 31st March 2023.

 

Details of proxy votes received prior to the meeting will be made available on the Company's website at https://bivictrix.com/investor-relations/. The proxy results were as follows:

 

 

  For more information, please contact:

 

BiVictriX Therapeutics plc


Tiffany Thorn, Chief Executive Officer

Michael Kauffman, Non-Executive Chairman

 

 

 

Email: info@bivictrix.com



SP Angel Corporate Finance LLP (NOMAD and Broker)

Tel: +44 (0) 20 3470 0470


David Hignell, Kasia Brzozowska (Corporate Finance)

Vadim Alexandre, Rob Rees (Sales and Broking)



 

Panmure Gordon (UK) Limited (Joint Broker)

 

Tel: +44 (0) 20 7886 2500


Rupert Dearden/Freddy Crossley/Emma Earl

 

Consilium Strategic Communications


Mary-Jane Elliott, Namrata Taak,

Genevieve Wilson, Emmalee Hoppe

Tel: +44 (0) 20 3709 5700

Email: Bivictrix@consilium-comms.com




 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni® fingerprints", on tumour cells, which are largely absent from healthy cells.

 

BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company's novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

 

Find out more about BiVictriX online at www.bivictrix.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGNKQBNPBKDPPK